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The endothelium lining the vasculature con-
stitutes a barrier maintaining the integrity be-
tween blood and interstitium and regulating 
extravasation of fl  uids and plasma proteins (1, 2). 
Changes in endothelial barrier function and 
increases in permeability are essential for neovas-
cularization and tissue repair (1). Tissue hypoxia 
is associated with the up-regulation of vascular 
endothelial growth factor (VEGF) that increases 
vascular permeability as a critical prerequisite 
step in new vessel formation (3). Contrastingly, 
during infl  ammatory responses, dysregulation of 
vascular permeability contributes to pathologi-
cal vascular leakage, often seen in conditions 
associated with edema such as in septic shock 
(1, 2). In this case, vasoactive substances, includ-
ing histamine, bradykinin, or TNF-α, are crucial 
in the regulation of endothelial permeability (2).
Endothelial permeability depends on 
  actomyosin-based cell contractility, as intracel-
lular stress fi  bers exert centripetal tension to 
induce permeability, and on the integrity of 
intercellular junctions (2, 4, 5). In response to 
vasoactive agents, myosin light chain (MLC) is 
phosphorylated and can thereby interact with 
actin fi  laments resulting in the formation of 
stress fi  bers (2). MLC phosphorylation is regu-
lated by MLC kinases and small GTPases (2).
Intercellular junctions (6) important for the 
endothelial barrier are as follows. (a) Adherens 
junctions are formed by cadherins that are linked 
to intracellular catenins. VE-cadherin–mediated 
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We recently reported that junctional adhesion molecule (JAM)-C plays a role in leuko-
cyte transendothelial migration. Here, the role of JAM-C in vascular permeability was 
investigated in vitro and in vivo. As opposed to macrovascular endothelial cells that 
constitutively expressed JAM-C in cell–cell contacts, in quiescent microvascular endo-
thelial cells, JAM-C localized mainly intracellularly, and was recruited to junctions upon 
short-term stimulation with vascular endothelial growth factor (VEGF) or histamine. 
Strikingly, disruption of JAM-C function decreased basal permeability and prevented 
the VEGF- and histamine-induced increases in human dermal microvascular endothelial 
cell permeability in vitro and skin permeability in mice. Permeability increases are essen-
tial in angiogenesis, and JAM-C blockade reduced hyperpermeability and neovasculariza-
tion in hypoxia-induced retinal angiogenesis in mice. The underlying mechanisms of 
the JAM-C–mediated increase in endothelial permeability were studied. JAM-C was 
essential for the regulation of endothelial actomyosin, as revealed by decreased F-actin, 
reduced myosin light chain phosphorylation, and actin stress fi  ber formation due to 
JAM-C knockdown. Moreover, the loss of JAM-C expression resulted in stabilization 
of VE-cadherin–mediated interendothelial adhesion in a manner dependent on the 
small GTPase Rap1. Together, through modulation of endothelial contractility and 
VE-cadherin–mediated adhesion, JAM-C helps to regulate vascular permeability and 
pathologic angiogenesis.
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cell–cell contacts are stabilized by the small GTPase Rap1 
and its eff  ector, the cyclic adenosine monophosphate (cAMP)-
activated guanidine exchange factor Epac, thereby decreasing 
paracellular permeability (7, 8). (b) Tight junctions that are 
located at the apical-most portion of the lateral interendothe-
lial membrane consist of three major families of transmem-
brane proteins, claudins, occludin, and junctional adhesion 
molecules (JAMs) (9).
JAMs, expressed in endothelial and epithelial cells, and on 
platelets and some leukocytes, consist of two Ig-like domains, 
and at their fi  nal COOH-terminus they have a class II PDZ 
domain–binding motif, predisposing them to interact with 
PDZ domain–containing molecules, such as ZO-1, ASIP/
PAR-3, or AF-6 (10, 11). JAM-A, JAM-B, and JAM-C reg-
ulate leukocyte–endothelial cell interactions by virtue of their 
ability to undergo heterophilic binding with the leukocyte 
integrins LFA-1, VLA-4, and Mac-1, respectively (10, 11). 
In addition, their junctional localization and their propensity 
to interact homophilically suggests that JAMs may participate 
in the regulation of tight junction formation in epithelial and 
endothelial cells and, consequently, in the regulation of para-
cellular permeability (10–12). A key role of JAM-A in epi-
thelial and endothelial barrier function has been shown 
(13–15). In contrast, ectopic JAM-C expression in MDCK 
or CHO cells revealed controversial data as to the function of 
JAM-C in permeability, whereas recent studies by us and 
others demonstrated that JAM-C may localize in endothelial 
junctions associated with ZO-1 and/or ASIP/PAR-3 (16–19). 
However, no study to date has addressed the role of JAM-C 
in the process of endothelial permeability.
These diverse observations prompted us to investigate the 
role of JAM-C in endothelial barrier function. We used mi-
crovascular endothelial cells as an appropriate in vitro model 
for permeability studies. Our fi  ndings clearly demonstrate 
that JAM-C mediates an increase in paracellular permeabil-
ity, through regulating actomyosin-dependent contractility 
and VE-cadherin–mediated cell–cell contacts in a Rap1-
  dependent manner. Furthermore, disruption of JAM-C function 
thereby blocked both infl   ammation- and   angiogenesis-
  associated increases in permeability in vitro and in vivo, 
and consequently JAM-C blockade in vivo, prevented 
neovascularization.
RESULTS
Regulation of JAM-C localization in microvascular 
endothelial cells
We fi  rst investigated the localization of JAM-C in endothe-
lial cells and whether it is aff  ected by vasoactive factors such 
as VEGF or histamine. In quiescent primary human dermal 
Figure 1.  JAM-C is recruited to the junctions of HDMECs after 
stimulation by VEGF or histamine. (A) Immunofl  uorescence analysis 
followed by confocal microscopy of the interendothelial contacts of 
HDMECs. Representative stainings of HDMECs that were incubated in the 
absence (−) or presence of VEGF (1 h, 50 ng/ml) or histamine (1 h, 
50 μM), showing the distribution of JAM-C and ZO-1. Double stained images 
were merged to analyze colocalization. (B) The surface versus total ex-
pression of JAM-C in nonpermeabilized versus permeabilized HDMECs, 
respectively, was analyzed by cell ELISA. HDMECs were pretreated without 
(−; open bars) or with VEGF (1 h, 50 ng/ml; filled bars) or histamine 
(1 h, 50 μM; gray bars) as indicated. JAM-C expression is shown as the per-
centage of control, defi  ned as the total JAM-C expression in the absence 
of any stimulus. Data are mean ± SD (n = 3) of one experiment typical of 
three separate experiments. (C) Analysis of the interendothelial contacts 
of HAECs was performed as in A. Representative immunofl  uorescence of 
HAECs that were incubated in the absence (−) or presence of VEGF (1 h, 
50 ng/ml) or histamine (1 h, 50 μM). The distribution of JAM-C and ZO-1 
is shown. Double stained images were merged to analyze colocalization.JEM VOL. 203, November 27, 2006  2705
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microvascular endothelial cells (HDMECs) JAM-C was 
mainly intracellular (Fig. 1 A) and absent from interendothe-
lial junctions. Interestingly, both VEGF and histamine in-
duced a rapid accumulation of JAM-C into the cell–cell 
borders, where it colocalized with ZO-1 (Fig. 1 A). To 
  analyze the eff  ect of VEGF and histamine on JAM-C local-
ization and expression, we compared total versus surface-
  exposed JAM-C in resting and stimulated endothelial cells. 
As shown in Fig. 1 B, under nonstimulated conditions  20% 
of JAM-C is cell surface associated (i.e., the remaining 80% is 
intracellular). This surface-associated JAM-C is apparently 
diff  usely distributed on the cell surface, as it does not loca-
lize in cell–cell junctions (Fig. 1 A). The amount of surface-
associated JAM-C increased to 60 and 70% upon stimulation 
with VEGF and histamine, respectively. Under these condi-
tions most surface-exposed JAM-C is localized to interendo-
thelial contacts (Fig. 1 A). In contrast, the expression of total 
JAM-C was not aff  ected by VEGF or histamine (Fig. 1 B), 
which was also verifi  ed by fl  ow cytometry and Western blot 
(unpublished data). Thus, although a small part of JAM-C 
that is surface associated may also concentrate to junctions 
upon stimulation, the major mechanism of JAM-C redistri-
bution to the junctions involves exocytosis from intracellular 
compartments. Interestingly, the same pattern of JAM-C lo-
calization was also observed in another microvascular endo-
thelial cell type, the human lung microvascular endothelial 
cells (HMVEC-L). In contrast, in two macrovascular endo-
thelial cell types, human umbilical vein endothelial cells 
(HUVECs) and human aortic endothelial cells (HAECs), 
JAM-C was constitutively located mainly at the interendo-
thelial contacts and its localization was not aff  ected by stimu-
lation with VEGF or histamine (Fig. 1 C and Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20051730/DC1). 
Thus, JAM-C localization in microvascular endothelial cells 
is intracellular and diff  ers from the junctional localization in 
macrovascular cells.
We then studied the kinetics of JAM-C redistribution to 
the cell–cell contacts in HDMECs. JAM-C appeared partially 
in junctions already 30 min after VEGF stimulation. The 
amount of junctional JAM-C peaked at 1 h after stimulation, 
whereas 2 h after VEGF stimulation junctional JAM-C stain-
ing was less and mostly disappeared thereafter. In the later 
time points and up to 24 h, JAM-C was mostly absent from 
the junctions. At this latter time point HDMEC junctions 
were largely disrupted (Fig. 2). The VEGF-mediated increase 
in HDMEC permeability showed a biphasic response: an 
early transient increase that peaked at 1 h and a delayed (>12 h) 
increase that peaked at 24 h (unpublished data and reference 
20). Together, JAM-C redistribution to the cell–cell contacts 
is a rapid and transient process.
Disruption of JAM-C function results in decreased 
endothelial permeability
We then investigated a potential role of JAM-C in microvas-
cular endothelial permeability by engaging two diff  erent 
  approaches to disrupt JAM-C function. First, we used the 
Figure 2.  Kinetics of JAM-C redistribution to the interendothelial 
junctions of HDMECs. Immunofl  uorescence analysis followed by confo-
cal microscopy of the interendothelial contacts of HDMECs. Representa-
tive stainings of HDMECs in the absence (0 h) or presence of VEGF 
(50 ng/ml) for different time points, showing the distribution of JAM-C 
and ZO-1. Note the disruption of the junctions at 24 h, as indicated by 
interendothelial gaps (arrows).2706  JAM-C AND ENDOTHELIAL PERMEABILITY | Orlova et al.
recombinant extracellular portion of JAM-C expressed as an 
Fc fusion protein, and second, knockdown of JAM-C ex-
pression was performed with siRNA targeted against human 
JAM-C. As shown in Fig. 3, A and B, siRNA against JAM-C 
results in an inhibition of JAM-C expression by 70% in HD-
MECs. In contrast, no alteration of ZO-1 or actin expression 
(Fig. 3 A) was observed by JAM-C knockdown. By assessing 
the infl  ux of FITC-dextran into the lower well in a Tran-
swell fi  lter system, Fc–JAM-C but not control Fc protein 
signifi  cantly reduced the VEGF- or histamine-induced in-
crease in HDMEC permeability (Fig. 3 C). In addition, 
knockdown of JAM-C expression resulted in a signifi  cant 
decrease (P < 0.05) in basal HDMEC permeability and   almost 
completely abolished the VEGF- and histamine-mediated 
HDMEC hyperpermeability (Fig. 3 D), whereas nontar-
geting control siRNA did not aff  ect HDMEC permeability 
(Fig. 3 D).
To rule out any unforeseen eff  ects of the siRNA ap-
proach and to prove the specifi  city of the eff  ects of JAM-C 
knockdown, further controls were engaged (Fig. S2, available 
at http://www.jem.org/cgi/content/full/jem.20051730/DC1). 
(a) A second siRNA targeting another JAM-C sequence 
was engaged, and a similar down-regulation of JAM-C con-
comitant with a reduction in endothelial permeability was 
observed. (b) Two siRNAs were used that had a single muta-
tion in their sequence compared with the two siRNAs 
  targeting JAM-C, thereby preventing silencing of JAM-C 
expression. In this case, JAM-C expression and endothelial 
permeability remained unaff  ected by these mutated siRNAs. 
(c) We engaged a siRNA down-regulating an irrelevant 
gene, cyclophilin, which mediated no changes in endothelial 
permeability. Thus, the observed eff  ect on the rescue of endo-
thelial barrier function mediated by JAM-C knockdown is 
specifi  c. Together, these results suggest that JAM-C mediates 
an increase in HDMEC permeability.
We then studied the eff  ect of JAM-C knockdown on 
tight junction molecule expression and HDMEC junction 
morphology. No change in the expression of ZO-1 (Fig. 3 A) 
or occludin (unpublished data) was found upon JAM-C 
down-regulation. In contrast, JAM-C knockdown prevented 
the VEGF- and histamine-mediated disintegration of endo-
thelial junctions, as observed by the more contiguous lining 
of interendothelial contacts in histamine- or VEGF-treated 
HDMECs that were transfected with the siRNA against 
JAM-C (Fig. 3 E; VEGF data is not shown). Thus, the func-
tion of JAM-C in HDMEC permeability is associated with 
morphological changes of the interendothelial contacts rather 
than changes in expression of junction-associated molecules.
JAM-C is important for actomyosin-driven 
endothelial contractility
We continued to study the underlying mechanisms for the 
rescue of endothelial barrier function caused by JAM-C 
knockdown. Endothelial barrier function depends on the ra-
tio of F-actin to G-actin, and disruption of endothelial barrier 
function is associated with rearrangement of cortical actin 
Figure 3.  JAM-C mediates an increase in paracellular permeability. 
(A) The expression of JAM-C, ZO-1, and actin was analyzed by Western blot in 
HDMECs transfected with siRNA against JAM-C or with control siRNA as indi-
cated. (B) The expression of JAM-C in HDMECs transfected with siRNA against 
JAM-C was 32 ± 7% of the expression of JAM-C in HDMECs transfected with 
control siRNA. Data are mean ± SD of six separate experiments. (C) HDMECs 
were incubated for 1 h without (100% control) or with VEGF (50 ng/ml) or 
histamine (50 μM) in the absence or presence of Fc (open bars) or Fc–JAM-C 
(gray bars) (each at 20 μg/ml). Permeability for FITC-conjugated dextran is 
expressed as the percentage of control, defi  ned as permeability in the absence 
of any stimulus or competitor. (D) HDMECs transfected with control siRNA 
(open bars) or with siRNA against JAM-C (gray bars) were incubated for 1 h 
without (−) or with VEGF (50 ng/ml) or histamine (50 μM). Permeability is 
expressed as the percentage of control, defi  ned as permeability of the control 
siRNA-transfected HDMECs in the absence of any stimulus. Data in C and D 
are mean ± SD (n = 3) of one experiment typical of three separate experi-
ments. *, P < 0.05; ns, not signifi  cant. (E) Representative immunofl  uorescence 
of histamine-treated HDMECs transfected with control siRNA or histamine-
treated HDMECs transfected with siRNA against JAM-C, as indicated, showing 
the distribution of JAM-C and ZO-1. Note the more contiguous lining of 
  interendothelial contacts in HDMECs upon JAM-C knockdown.JEM VOL. 203, November 27, 2006  2707
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and increased formation of stress fibers (2, 4, 21). Upon 
JAM-C knockdown in HDMECs, a dramatic decrease in 
F-actin was observed (Fig. 4 A). Consistently, there was a 
decrease in the F-actin to G-actin ratio in cells transfected 
with siRNA against JAM-C compared with cells transfected 
with control siRNA (Fig. 4 B). Histamine or VEGF increased 
stress fi  ber formation in endothelial cells (Fig. 4 A) as also in-
dicated by the increase in F-actin to G-actin ratio (Fig. 4 B; 
VEGF data not shown); however, consistent with previous 
reports this change in stress fi  ber intensity in endothelial cells 
upon stimulation was not dramatic (21–24). This VEGF- and 
histamine-induced increase in actin stress fi  ber formation was 
prevented by JAM-C down-regulation (Fig. 4 A; VEGF data 
not shown).
Stress fi  ber formation depends on the phosphorylation of 
the regulatory MLC that regulates the interaction of myosin 
with actin (2,21). Western blotting with an anti–phospho-
MLC antibody revealed a threefold decrease in MLC phos-
phorylation as a result of the down-regulation of JAM-C 
expression (Fig. 4 C). JAM-C knockdown also prevented the 
histamine-induced MLC phosphorylation (Fig. 4 D). In con-
trast, other signaling pathways, such as extracellular signal-
regulated kinase  1 phosphorylation were not aff  ected  by 
JAM-C knockdown (unpublished data). Thus, consistent 
with its role in endothelial barrier function JAM-C regulates 
processes related to actomyosin-driven cell contractility.
JAM-C knockdown increases Rap1 activity 
and VE-cadherin–mediated cell–cell adhesion
Small GTPases have been implicated in the regulation of vas-
cular permeability (2, 4, 5), and JAM-C was recently shown 
to interact with and regulate the activity of Cdc42 during 
spermatid polarization (25). Therefore, we studied whether 
JAM-C knockdown alters the activity of small GTPases. 
JAM-C knockdown left the activity of Cdc42, Rac, and Ras 
unchanged (Fig. 5 A and unpublished data). In contrast, a 
three- to fourfold up-regulation in the endogenous Rap1 ac-
tivity was found upon JAM-C down-regulation in HDMECs 
(Fig. 5 A). Recent fi  ndings linked the Epac/Rap1 pathway 
with the strength of the adhesive contacts in adherens junc-
tions and particularly with the homotypic VE-cadherin–
  mediated interactions between adjacent endothelial cells 
(7, 8). Consistently, the loss of JAM-C expression resulted in 
a threefold increase of the homophilic adhesive interaction of 
VE-cadherin (Fig. 5 B). In contrast, adhesion to platelet en-
dothelial cell adhesion molecule (PECAM)-1, a molecule 
also involved in endothelial cell–cell contacts (26), was not 
aff  ected by JAM-C knockdown (Fig. 5 B). VE-cadherin pro-
tein expression was not changed because of JAM-C knock-
down (Fig. 5 C). In addition, β1-integrin expression and 
localization that may be regulated by Rap1 (13) were not af-
fected by the expression level of JAM-C (unpublished data).
Besides the Epac/Rap1 pathway, protein kinase A (PKA) 
activity is another cAMP-dependent pathway   regulating 
endothelial barrier function (27). We therefore assessed 
the contribution of either pathway in the rescue of barrier 
Figure 4.  JAM-C is essential for HDMEC contractility. (A) Repre-
sentative immunofl  uorescence of Rhodamine-conjugated phalloidin 
showing the distribution of F-actin in buffer- or histamine-treated 
HDMECs transfected with control siRNA or with siRNA against JAM-C. 
Nuclei are shown by DAPI staining. (B) The F-actin to G-actin ratio of 
HDMECs transfected with control siRNA or with siRNA against JAM-C in 
the   absence (open bars) or presence of histamine (fi  lled bars) is shown. 
The F-actin to G-actin ratio is expressed as the percentage of control, 
defi  ned as the F-actin to G-actin ratio of the control siRNA-transfected 
HDMECs in the absence of histamine. Data are mean ± SD (n = 3) of 
three separate experiments. *, P < 0.05; #, P < 0.01. (C) The phosphoryla-
tion of MLC was analyzed by Western blot with antibody against phos-
pho-MLC or total MLC in HDMECs transfected with control siRNA or with 
siRNA against JAM-C. A representative immunoblot for phospho-MLC is 
shown. The insert shows densitometric analysis of phospho-MLC/total 
MLC in HDMECs transfected with control siRNA or with siRNA against 
JAM-C. Data are shown relative to control (phospho-MLC/total MLC in 
HDMECs transfected with control siRNA was set as 1) and are mean ± SD 
of three separate experiments. (D) MLC phosphorylation was analyzed as 
in C in HDMECs transfected with control siRNA or with siRNA against 
JAM-C in the absence (0 min) or presence of histamine for different time 
points as indicated.2708  JAM-C AND ENDOTHELIAL PERMEABILITY | Orlova et al.
  function by JAM-C knockdown. Whereas JAM-C knock-
down resulted in an up-regulation of Rap1 activity (Fig. 5 A), 
the PKA pathway remained unaff  ected as assessed by deter-
mining the phosphorylation of the transcription factor CREB 
(unpublished data). The following observations further 
strengthened the role of Rap1 in mediating the eff  ect of 
JAM-C on endothelial barrier function. (a) The cAMP-
  elevating agents forskolin/rolipram and pharmacologic up-
regulation of Rap1 activity with an Epac activator (O-Me-cAMP) 
decreased basal permeability of HDMEC monolayers. The 
eff  ect of JAM-C knockdown to decrease endothelial permea-
bility was comparable to the eff  ect of O-Me-cAMP (Fig. 6 A). 
(b) VE-cadherin–mediated cell adhesion was not only in-
creased by JAM-C knockdown but also by O-Me-cAMP, 
but not by a PKA activator (Sp-8-Br-cAMPS) (Fig. 6 B). 
(c) The decrease in endothelial permeability and the   increase 
in VE-cadherin–mediated adhesiveness caused by JAM-C 
knockdown were largely prevented by down-regulation of 
Rap1 expression and Rap1 activity by engaging a siRNA 
against Rap1 but not by inhibition of PKA activity by a PKA 
inhibitor (Rp-8-Br-cAMPS) (Fig. 6, C and D, and unpub-
lished data). Therefore, we conclude that JAM-C knockdown 
stabilizes VE-cadherin–mediated adhesive interendothelial 
contacts and rescues endothelial barrier function in a Rap1-
dependent manner.
Consistent with the previous data, the overexpression 
of mouse JAM-C in microvascular endothelial cells reversed 
the increase of VE-cadherin–mediated cell–cell adhesion 
caused by the knockdown of human JAM-C (Fig. 7). These 
data underline the specifi  city of the observed eff  ects medi-
ated by JAM-C knockdown and indicate that mouse JAM-C 
may undertake similar functions in endothelial cells as 
human JAM-C.
JAM-C blockade decreases microvascular permeability 
in vivo and hypoxia-induced retinal angiogenesis
To assess the function of JAM-C in vascular permeability in 
vivo, we studied the eff  ect of JAM-C blockade on VEGF- 
and histamine-mediated vascular leakage in mice. A modi-
fi   ed Miles vascular permeability assay was performed, in 
which soluble mouse JAM (smJAM)-C or the control 6xHis 
peptide were injected i.p. 1 h before intradermal injection of 
VEGF or the compound 48/80 that mediates mast cell de-
granulation (28). Spectrophotometric measurements of the 
amount of extravasated Evans blue revealed a four- to   fi  vefold 
and a six- to sevenfold increase in vascular permeability 
by VEGF or compound 48/80, respectively. Interestingly, 
smJAM-C inhibited vascular permeability by at least 50% 
in both cases (Fig. 8 A), whereas the control 6xHis peptide 
had no eff  ect (unpublished data). As permeability changes are 
crucial in cutaneous infl  ammatory reactions, we investigated 
the role of smJAM-C in delayed-type hypersensitivity re-
sponses that were elicited in mice by using oxazolone as a 
sensitizing agent. Treatment with smJAM-C signifi  cantly re-
duced macroscopic ear swelling and local edema as assessed 
by the increased Evans blue leakage in the challenged ear 
above the baseline of the nonchallenged contralateral con-
trol ear were signifi  cantly reduced by smJAM-C treatment 
(unpublished data).
Besides infl  ammatory reactions, increases in vascular per-
meability are important in neovascularization. We therefore 
examined the role of JAM-C in pathological retinal neovas-
cularization in the mouse model of hypoxia-induced retina 
angiogenesis (retinopathy of prematurity [ROP]). First, 
smJAM-C but not the control 6xHis peptide inhibited the 
Figure 5.  JAM-C regulates Rap1 activity and VE-cadherin–
  mediated contacts. (A) Pull-down assays were performed to isolate active 
GTP-bound Rap1 or Ras. Western blots for Rap1 or Ras revealed increased 
active Rap1 in HDMECs transfected with siRNA against JAM-C compared 
with the HDMECs transfected with control siRNA, whereas active Ras was 
unchanged. In contrast, no change in the total Rap1 or Ras level was 
observed. The insert shows densitometric analysis of the ratio between 
active and total Ras or Rap1 in HDMECs transfected with siRNA against 
JAM-C (gray bars) or with control siRNA (open bars). Data are shown 
relative to control (active GTPase/total GTPase in HDMECs transfected 
with control siRNA was set as 1) and are mean ± SD of three separate 
experiments. (B) The adhesion of HDMECs transfected with control siRNA 
(open bars) or HDMECs transfected with siRNA against JAM-C (gray bars) 
to immobilized BSA, control Fc protein, Fc–VE-cadherin, or Fc–PECAM-1 
is demonstrated. Adhesion is shown as the percentage of adherent cells. 
Data are mean ± SD of a typical experiment; similar results were ob-
tained in three separate experiments. (C) The expression of VE-cadherin 
was analyzed by Western blot in HDMECs transfected with siRNA against 
JAM-C or with control siRNA as indicated.JEM VOL. 203, November 27, 2006  2709
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increase in retinal vascular permeability that develops during 
the course of the ROP model. In particular, leakage of Evans 
blue in retinas of 13-d-old (p13) mice was reduced by 45% in 
animals treated with smJAM-C (Fig. 8 B). Second, treatment 
with smJAM-C but not with the control 6xHis peptide from 
day p12 up to p16 reduced retinal angiogenesis by 50% (Fig. 
8 C). Immunohistochemical analysis of axial retinal sections 
demonstrated a substantial reduction in the extent of neovas-
cularization in mice given smJAM-C compared with mice 
treated with control 6xHis peptide. In addition, analysis of 
retina whole mounts indicated that p17 retinas from smJAM-
C–treated mice demonstrated a marked reduction in the 
number of neovascular tufts compared with control-treated 
animals (Fig. S3 and S4, http://www.jem.org/cgi/content/
full/jem.20051730/DC1). Thus, smJAM-C reduced the 
number and the pathologic morphology of the new vessels in 
the retina. Together, these data demonstrate that smJAM-C 
inhibits infl  ammation- and angiogenesis-related hyperperme-
ability and pathological retinal neovascularization in vivo.
DISCUSSION
Our present fi  ndings clearly demonstrate that JAM-C regu-
lates both infl  ammation- and angiogenesis-related endothelial 
permeability. In particular, JAM-C mediates an increase in 
endothelial permeability by modulating actomyosin-based 
endothelial contractility and through regulation of VE-
  cadherin–mediated cell–cell contacts in a Rap1-dependent 
manner. Consistently, disruption of JAM-C function by soluble 
JAM-C in vivo decreased vascular permeability in the skin 
during delayed-type hypersensitivity responses and in the 
retina during hypoxia-driven retinal neovascularization, and 
reduced retina angiogenesis.
To date, transmembrane molecules of the tight junctions 
were thought to function as gatekeepers by interacting in a 
homotypic fashion (13–15); thus, our fi  ndings were some-
what surprising. To our knowledge, JAM-C was defi  ned 
here as the fi  rst junctional molecule that can mediate an in-
crease in permeability. JAM-C knockdown mediated a res-
cue of endothelial barrier function under basal conditions and 
prevented VEGF- and histamine-mediated disintegration of 
endothelial junctions.
Interestingly, the subcellular localization of JAM-C in 
microvascular endothelial cells was found to be divergent 
from macrovascular endothelial cells. Consistent with our 
previous reports and those by others (16, 17), JAM-C in 
macrovascular endothelial cells was localized in the interen-
dothelial junctions. In contrast, microvascular endothelial 
JAM-C was mainly intracellular and redistributed rapidly and 
transiently to the cell–cell contacts upon stimulation with 
Figure 6.  The rescue of endothelial barrier function and the stim-
ulation of VE-cadherin–mediated adhesiveness caused by JAM-C 
knockdown is dependent on the activity of Rap1. (A) HDMECs were 
transfected with control siRNA (open bars) or with siRNA against JAM-C 
(gray bar). Permeability of HDMECs transfected with control siRNA was 
analyzed in the absence (−) or in the presence of forskolin (10 μM)/rol-
ipram (20 μM), or the Epac activator O-Me-cAMP (200 μM). Permeability 
is expressed as the percentage of control, defi  ned as permeability of the 
control siRNA-transfected HDMECs in the absence of any competitor. 
(B) The adhesion of HDMECs transfected with control siRNA in the absence 
(open bars), or in the presence of the PKA activator (Sp-8-Br-cAMPS, 
200 μM, fi  lled bars), or in the presence of the Epac activator O-Me-cAMP 
(200 μM, hatched bars), or of HDMECs transfected with siRNA against 
JAM-C (gray bars) to immobilized Fc–VE-cadherin or Fc–PECAM-1 is demon-
strated. Adhesion is shown as the percentage of adherent cells. (C) HD-
MECs were transfected with control siRNA (open bars), with control siRNA 
together with siRNA against Rap1 (shaded bars), with siRNA against JAM-C 
(gray bars), or with siRNA against JAM-C together with siRNA against 
Rap1 (hatched bars). Permeability of HDMECs was analyzed in the absence 
(−) or presence of VEGF (50 ng/ml) or histamine (50 μM). Permeability is 
expressed as the percentage of control, defi  ned as permeability of the 
control siRNA-transfected HDMECs in the absence of any stimulus. 
(D) The adhesion of HDMECs transfected with control siRNA or siRNA against 
JAM-C to immobilized Fc–VE-cadherin or Fc–PECAM-1 is shown in the 
absence (open bars), or in the presence of the PKA inhibitor (Rp-8-Br-
cAMPS, 200 μM, shaded bars), or in the presence of Rap1 knockdown 
with siRNA against Rap1 (gray bars). Adhesion is shown as the percentage 
of adherent cells. Data are mean ± SD of a typical experiment; similar 
results were obtained in three separate experiments.2710  JAM-C AND ENDOTHELIAL PERMEABILITY | Orlova et al.
VEGF or histamine. Our fi  ndings are in line with the diver-
sity among endothelial cells from diff  erent vascular beds espe-
cially with respect to the regulation of paracellular permeability 
or leukocyte transendothelial migration (29, 30). By immu-
nogold electron microscopy we found intracellular JAM-C 
in HDMECs to be associated with structures some, but not 
all, of which resembled Weibel-Palade bodies (unpublished 
data). The complete subcellular localization of JAM-C must 
be investigated in a future study. The regulated localization 
of JAM-C and its recruitment to the interendothelial contacts 
correlate and coincide with the role of JAM-C in regulating 
VEGF- and histamine-induced permeability. However, al-
though the redistribution of JAM-C to the junctions may be 
relevant, it is clearly not essential for the eff  ects of JAM-C on 
endothelial barrier function, as basal nonstimulated endothe-
lial permeability was also decreased by JAM-C knockdown. 
In fact, intracellular JAM-C clearly regulates signaling, such 
as the Rap1 pathway, and participates in the regulation of ac-
tin stress fi  ber formation. This may be attributed to the pro-
pensity of JAM-C to be associated with AF-6 or other 
scaff  olding molecules that may provide a link between intra-
cellular JAM-C and these signaling pathways. Further studies 
addressing the detailed molecular mechanism for the intra-
cellular traffi   cking of JAM-C and the importance of JAM-C 
  localization for endothelial barrier function in microvascular 
versus macrovascular endothelial cells are required.
JAM-C knockdown in microvascular endothelial cells 
  resulted in a decrease in F-actin and prevented stress fi  ber 
formation. In line with these observations JAM-C knockdown 
decreased the phosphorylation of MLCs. Of note, the changes 
in actomyosin caused by JAM-C knockdown were consider-
ably higher than the decrease in basal endothelial permeabil-
ity, indicating that changes in stress fi  ber formation may only 
loosely correspond to permeability changes, although these 
two processes may be functionally linked. By regulating the 
status of actomyosin, JAM-C may modulate actomyosin-
driven contractility, although endothelial contractility was 
not directly assessed in the present study. Furthermore, 
knockdown of JAM-C led to the up-regulation of Rap1 ac-
tivity, whereas the activity of other GTPases remained unaf-
fected. Rap1 is involved in the formation and maintenance of 
cadherin-mediated cell–cell contacts and adherens junctions 
in endothelial and epithelial cells (7, 8, 31, 32), thereby im-
proving barrier function. The homophilic ligation of E-cad-
herin in epithelial cells induces Rap1 activation, and vice 
versa, the affi   nity and avidity of cadherin-mediated contacts 
Figure 7.  Overexpression of mouse JAM-C reverses the increase of 
VE-cadherin–mediated adhesiveness caused by JAM-C knockdown. 
(A) The expression of mouse JAM-C and human JAM-C was analyzed by 
Western blot in HDMECs transfected with control siRNA (1), in HDMECs 
transfected with control siRNA, and with mouse JAM-C (2), in HDMECs 
transfected with siRNA against JAM-C (3), or in HDMECs transfected with 
siRNA against JAM-C and with mouse JAM-C (4) as indicated. (B) The 
adhesion of HDMECs transfected with control siRNA (open bars), of 
HDMECs transfected with control siRNA and with mouse JAM-C (shaded 
bars), of HDMECs transfected with siRNA against JAM-C (gray bars), or of 
HDMECs transfected with siRNA against JAM-C and with mouse JAM-C 
(hatched bars) to immobilized control Fc protein, Fc–VE-cadherin, or 
Fc–PECAM-1 is shown. Adhesion is shown as the percentage of adherent 
cells. Data are mean ± SD of a typical experiment; similar results were 
obtained in three separate experiments.
Figure 8.  Inhibition of JAM-C decreases microvascular permeability 
in vivo and hypoxia-induced retina angiogenesis. (A) Skin perme-
ability (as assessed by leakage of Evans blue) induced by intradermal in-
jection of VEGF or compound 48/80 is shown without (open bars) or with 
pretreatment with smJAM-C (gray bars). The control 6xHis peptide did not 
affect VEGF- or histamine-induced permeability. Permeability is shown as 
the percentage of control, defi  ned as the skin permeability after intrader-
mal injection with buffer in the absence of competitors, and data are 
shown as mean ± SD (n = 5 mice). (B and C) Mice were subjected to the 
ROP model. (B) The permeability of the retina was assessed by the leakage 
of Evans blue on day p13. 6 h before assessing the leakage of Evans blue, 
mice were treated i.p. with buffer, the control 6xHis peptide, or smJAM-C. 
The leakage of Evans blue was quantifi  ed as absorbance/dry weight of the 
retina, and data are represented as the percentage of control (buffer-
treated mice) and are mean ± SD (n = 5 mice). (C) Retinal neovasculari-
zation was quantifi  ed on day p17 as described in Materials and methods. 
Mice were treated from day p12 until day p16 once daily 
i.p. with buffer, the control 6xHis peptide, or smJAM-C. Retinal neovascu-
larization is presented as the percentage of control, defi  ned as neovascu-
larization in the presence of buffer only. Data are mean ± SD (n = 5 
mice). *, P < 0.05; ns, not signifi  cant.JEM VOL. 203, November 27, 2006  2711
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may be modulated by Rap1-triggered inside-out signaling 
(31–34). Consistently, JAM-C knockdown strengthened 
VE-cadherin–mediated cell–cell contacts. This was a Rap1-
dependent process, as down-regulation of Rap1 activity 
largely prevented the rescue of endothelial barrier function 
and the increase in VE-cadherin–mediated contacts caused 
by JAM-C knockdown. In contrast, the eff  ects of JAM-C 
down-regulation were not altered by inhibition of the activ-
ity of PKA, another known regulator of endothelial barrier 
function (27).
Interestingly, JAM-A, which functions to decrease para-
cellular permeability in endothelial and epithelial cells (13–15), 
was recently found to regulate Rap1 activity in an opposite 
way to JAM-C, as JAM-A knockdown decreased Rap1 
  activity in epithelial cells (14). Although, these authors did 
not study cadherin-mediated cell–cell contacts, their   fi  ndings, 
together with our present data, enable a new mechanism 
for the regulation of vascular permeability by JAMs to be 
  envisioned: JAM-A acts as a gatekeeper of the endothelial 
contacts, as its homophilic interaction may participate in the 
tight junction–mediated adherence, and through stimulating 
Rap1 it may promote the integrity of adherens junctions. 
The counter-player, JAM-C, down-regulates Rap1 activity 
and shifts the equilibrium toward the disruption of VE-
  cadherin–mediated intercellular contacts. In this intriguing 
scenario, which needs further experimental proof, it is strik-
ing that two structurally very similar molecules, JAM-A and 
JAM-C, act in an opposite manner to regulate the balance of 
active versus nonactive Rap1.
The herein reported destabilization of adherens junctions 
by JAM-C may also be operative in the function of JAM-C 
to promote transendothelial migration. Besides its interaction 
with leukocyte Mac-1 during transmigration (16), junctional 
JAM-C may disrupt adherens junctions and increase the in-
fl  ux of leukocytes. This is consistent with recent fi  ndings 
from transgenic JAM-C–overexpressing mice that revealed 
increased accumulation of infl   ammatory cells (35). More-
over, we have previously shown that soluble JAM-C blocks 
neutrophil transendothelial migration in vitro and in vivo 
(16). Although soluble JAM-C acts as an inhibitor of Mac-1, 
it cannot be overlooked that the inhibition of transmigration 
by soluble JAM-C in vivo may also be attributed to decreased 
endothelial permeability.
Our fi  ndings that JAM-C regulates actin polymerization 
and actomyosin contractility and VE-cadherin–  dependent 
cell–cell contacts become even more evident in light of 
two very recent publications deconstructing the cadherin–
catenin–actin complex (36, 37). In particular, α-catenin 
assembled into the cadherin–catenin complex cannot bind 
actin. Instead, the recruitment of α-catenin to the adherens 
junctions upon cadherin ligation functions as a molecular 
switch to ultimately inhibit actin polymerization. This mo-
lecular mechanism would explain our present fi  nding that 
the increase in VE-cadherin adhesiveness caused by JAM-C 
knockdown is accompanied by a decrease in F-actin; how-
ever, direct experimental evidence needs to be generated for 
this hypothesis. Furthermore, the fi  ndings of these two re-
cent publications (36, 37) highlight the emergence of alter-
nate mechanisms that regulate adherens junctions such as the 
one described in the present study. In epithelial cells, nectins, 
through their homophilic interaction, regulate the stability 
of cadherin-based cell–cell contacts both via AF-6 and by 
modulating the activity of small GTPases, particularly Rap1 
(38). JAMs may take over a similar function in regulating 
the maintenance of adherens junctions in endothelial cells, 
thereby fi  ne tuning vascular permeability. In addition, the in-
ability of the cadherin–catenin complex to interact with actin 
(36, 37) highlights the importance of alternate links between 
these two components. AF-6 may operate as a potential link 
between the actin cytoskeleton, adherens junctions, and 
Rap1 (38–40) and may interact with the COOH-terminus 
of nectins and JAMs (reference 41 and unpublished data). 
This hypothesis requires further investigation. Nevertheless, 
our present work uncovers the fi  rst functional link between 
JAMs and VE-cadherin and a novel crosstalk between tight 
and adherens junctions that may open new directions for 
studies of endothelial barrier function.
MATERIALS AND METHODS
Production of soluble recombinant JAM-C proteins. Recombinant 
smJAM-C was produced as a 6xHis-tagged protein in Schneider Drosophila 
S2 cells (Invitrogen) as previously described (16). Control 6xHis peptide was 
purchased from Covance. Fc fusion protein of soluble recombinant human 
JAM-C (Fc–JAM-C) was produced in High-Five Insect cells as previously 
described (42). Fc–intercellular adhesion molecule -1 was from R&D Sys-
tems, and Fc control protein was purchased from Alexis.
Cell culture and transfection. HDMECs, HMVEC-L, HAECs, and 
HUVECs were purchased from Cambrex and cultivated as described by the 
supplier. All endothelial cells were used in low passages (up to the fourth 
passage). Cells were grown on culture dishes precoated with 0.2% gelatin 
(Sigma-Aldrich). For transfections, the following chemically synthesized du-
plex siRNAs were engaged: two siRNAs directed against human JAM-C, 
two respective control siRNAs with a single nucleotide mutation, thereby 
preventing JAM-C silencing, a siRNA against cyclophilin, a nontargeting 
control siRNA (siGENOME –hJAM3#1 and siGENOME –hJAM3#2, 
siJAM3#1mut, siJAM3#2mut, si-Cyclophilin-B and siCONTROL nontar-
geting siRNA#1, respectively) (Dharmacon), and a siRNA against Rap1a 
(siRap1 Eurogentec). Single siRNAs or combinations of two diff  erent 
siRNA were transfected at a concentration of 100 nM using Oligofectamine 
reagent (Invitrogen) in OptiMEM medium (Invitrogen). Cells were engaged 
48–72 h after transfection in experiments as described below. Transient 
DNA transfections of microvascular endothelial cells were performed with a 
nucleofection kit (Amaxa Ink). Mouse full-length JAM-C cloned into 
pcDNA3.1-Zeo vector was purifi  ed with the EndoFree Plasmid Maxi kit 
(QIAGEN). Cells were nucleofected with 2 μg of DNA according to the 
manufacturer’s protocol and assayed 48 h after nucleofection.
Adhesion assay. Adhesion of HDMECs to immobilized Fc, Fc–VE-
  cadherin (R&D Systems), and Fc–PECAM-1 (provided by P.J. Newman, 
Blood Research Institute, Milwaukee, WI) was tested according to a previ-
ously described protocol (43, 44). In brief, wells were coated with Fc, Fc–
VE-cadherin, Fc–PECAM-1, or BSA (each 20 μg/ml) in PBS and blocked 
with 3% BSA. Fluorescence-labeled HDMECs (3 × 104/well) were washed 
twice and added to the immobilized proteins for 60 min at 37°C in the ab-
sence or presence of eff  ectors. After washings, adhesion of cells was quanti-
fi  ed as the percentage of total cells added using a fl  uorescence microplate 
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Cell ELISA for the comparison of total versus surface JAM-C. Cell 
ELISA for the comparison of surface versus total JAM-C was performed ac-
cording to a previously described protocol with modifi  cations (42). In brief, 
HDMECs were grown to confl  uence on 24-well plates. Thereafter, cells 
were washed and incubated in the absence or presence of stimuli in serum-
free medium for 1 h at 37°C. After incubation, cells were washed twice with 
PBS and fi  xed with 4% PFA. After fi  xation, a part of the wells was permea-
bilized with 0.1% Triton X-100. After washing and blocking with PBS con-
taining 3% BSA for 1 h at 22°C, a polyclonal goat anti–human JAM-C 
(R&D Systems) was incubated, followed by addition of appropriate second-
ary peroxidase-conjugated antibody and the substrate ABTS. Surface expres-
sion (in fi  xed cells) versus total expression (in fi  xed and permeabilized cells) 
was quantitated at 405 nm, and nonspecifi  c binding (binding of the second-
ary antibody to wells, in which the fi  rst antibody was omitted) was used as 
blank and was subtracted to calculate specifi  c binding.
Endothelial cell permeability. HDMEC permeability was studied as pre-
viously described (20, 44). In brief, cells were grown to confl  uent monolay-
ers on gelatin-coated membranes in double-chamber tissue culture plates 
(Transwell membrane, 0.4 μM pore size; Corning Costar). After 2 d, cham-
bers were examined microscopically for integrity and uniformity of endo-
thelial monolayers, medium was switched to serum-free conditions and the 
stimuli/competitors, VEGF (50 ng/ml; R&D Systems), histamine (50 μM; 
Calbiochem), the Epac activator 8-pCPT-2′-O-Me-cAMP (O-Me-cAMP; 
100–500 μM; Alexis Biochemicals), forskolin (10 μM; Calbiochem), ro-
lipram (20 μM; Calbiochem), the PKA-specifi  c activator Sp-8-Br-cAMPS 
(200 μM; Calbiochem), and the PKA inhibitor Rp-8-Br-cAMPS (200 μM; 
Calbiochem), were added in quadruplicate cups at designated times. At 
the end of the incubation period, FITC-conjugated dextran (1 mg/ml, Mr 
42,000; Sigma-Aldrich) was added to the upper chambers, and fl  uores-
cence in the lower chamber was measured 1 h later with a fl  uorescence 
reader (BIOTEK).
Immunofl  uorescence. HDMECs were grown to confl  uence on 0.2% 
  gelatin-coated glass coverslips and then incubated in serum-free medium 
with stimuli for diff  erent time points as indicated in the fi  gure legends. For 
the staining of F-actin, cells were washed, fi  xed in 4% PFA for 10 min, and 
permeabilized with 0.1% Triton X-100 in PBS for 5 min. Cells were blocked 
with 1% BSA, 5% goat serum in PBS for 1 h at 22°C. Cells were then incu-
bated with AlexaFluor568-conjugated Phalloidin (Molecular Probes) in 
blocking buff  er for 30 min at 22°C. The same protocol was used for the de-
tection of JAM-C and ZO-1 except that cells were fi  xed in ice-cold metha-
nol for 20 min at −20°C, and the mAbs Gi11 against JAM-C (43) or the 
rabbit anti–ZO-1 (Zymed) were engaged followed by appropriately conju-
gated secondary antibodies. Thereafter, cells were washed and mounted in 
Fluoromount-G (SouthernBiotech). Confocal fl   uorescence images were 
captured using a Zeiss laser scanning microscope.
Measurement of endogenous activity of small GTPases. HDMECs 
(transfected with siRNA against JAM-C or control siRNA) were grown to 
confl  uence. For assaying the activity of Cdc42/Rac, Ras, and Rap1, cells 
were lysed, and active Cdc42/Rac, Ras, and Rap1 were precipitated with 
PAK-PBD beads, Raf-PBD beads (Cytoskeleton), or Ral-RBD beads (Up-
state Biotechnology), respectively, for 45 min at 4°C. Precipitates were then 
washed, resuspended in 40 μl of 2× sample buff  er, boiled for 5 min at 
100°C, and separated by 12% SDS-PAGE. Antibodies against Cdc42 or 
Rac-1 (BD Biosciences) or antibodies against Ras or Rap1 (Upstate Bio-
technology) were used for detection.
Western blot analysis. HDMECs were washed once with ice-cold PBS 
and lysed in RIPA buff  er (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.25% Na-deoxycholate, 0.1% SDS, 25 mM 
NaF, 1 mM sodium orthovanadate, and protease inhibitors), boiled, and 
separated by SDS-PAGE followed by protein transfer to nitrocellulose mem-
branes. Membranes were blocked for 1 h at 22°C and incubated with anti-
bodies against ZO-1, VE-cadherin (Zymed), MLC, phospho-MLC, 
p-ERK1/2, phospho-CREB (Cell Signaling), β-actin (Abcam), JAM-C 
(mAb Gi11), CD29 (Santa Cruz Biotechnology, Inc.), or the goat anti–
mouse JAM-C (R&D Systems). After washings, blots were incubated with 
appropriate peroxidase-coupled secondary antibodies (Abcam) and devel-
oped with ECL Plus reagent (GE Healthcare).
Measurement of the F-actin to G-actin ratio. The F-actin to G-actin 
ratio was determined as previously described (45). HDMECs were grown to 
confl  uence on 0.2% gelatin precoated 24-well plates and stimulated with 
VEGF or histamine as described for 1 h. Thereafter cells were washed and 
fi  xed with 4% PFA, followed by permeabilization with 0.1% Triton X-100. 
Cells were blocked with 1% BSA, 5% goat serum in PBS for 1 h at 22°C and 
double stained with AlexaFluor488 DNase I (for monomeric G-actin) and 
AlexaFluor568 Phalloidin (for polymeric F-actin) (Molecular Probes) for 30 
min at 22°C and then rinsed three times with PBS. Quantifi  cation of G-actin 
and F-actin was performed with a spectrofl  uorometer (BIOTEK).
Hypoxia-induced retinal vascularization (ROP model). Studies were 
performed as previously described (44). In brief, 7-d-old (p7) C57BL/6 mice 
were exposed to 75% oxygen for 5 d in an incubator (BioSpherix) with their 
nursing mothers. At p12, mice were returned to room air. From p12 until 
p16, mice were given i.p. injections of smJAM-C, the control 6xHis peptide 
(each 30 μg/mouse), or buff  er alone once daily (fi  ve mice/group). Mice 
were killed at p17, and eyes were processed for quantifi  cation of preretinal 
neovascular nuclei as described (44). To quantify retinal neovascularization, 
6-μm paraffi   n-embedded sections were stained with PAS and hematoxylin, 
and 10 intact sections of equal length, each 18 μm apart, were evaluated. All 
retinal vascular cell nuclei anterior to the internal limiting membrane were 
counted in each section by an observer blinded to the protocol. The mean 
of the 10 counted sections represents the average neovascular nuclei per sec-
tion per eye. No neovascular cell nuclei anterior to the internal limiting 
membrane are observed in normal “room air” mice (44).
Quantifi  cation of vascular permeability in the retina of p13 mice sub-
jected to the ROP model was performed by measuring the leakage of Evan’s 
blue, according to a previously described protocol (44, 46). In brief, p13 
mice subjected to the ROP model and controls were anesthetized, and 100 μl 
of Evan’s blue (30 mg/kg) was injected into the left ventricle. After removal 
of the eyes and careful dissection of the retinas, the dye was extracted from 
each retina by incubation in formamide for 48 h at 55°C. Leakage of Evan’s 
blue was expressed as absorbance at 620 nm/dry weight of the retina. Animal 
studies were approved by the NCI Animal Care and Use Committee 
(Bethesda, MD) and the Governmental Offi   ce Karlsruhe (Germany).
In vivo vascular permeability assay. A modifi  ed Miles assay was per-
formed as described previously (47). Mice were pretreated by i.p. injection 
of control 6xHis peptide or smJAM-C (each 100 μg/mouse) 60–90 min be-
fore the experiment. Mice were anesthetized and VEGF (100 ng) or com-
pound 48/80 (10 μg; Sigma-Aldrich) in 50 μl PBS was injected intradermally 
into the shaved back skin. After 30 min, 100 μl Evans blue dye in 0.9% NaCl 
(30 mg/kg) was injected into the left ventricle. After 10 min mice were 
killed and the marked region of skin that included the area of the intradermal 
injection was removed. Evans blue dye was extracted from the skin and the 
absorbance of extracted dye was measured at 620 nm as described in Hypoxia-
induced retinal vascularization (ROP model).
Statistical analysis. Data were compared using the Student’s t test and 
ANOVA with post-hoc analysis as appropriate; p values <0.05 were re-
garded as signifi  cant.
Online supplemental material. Fig. S1 shows the localization of JAM-C 
in HUVEC and HMVEC-L. Fig. S2 shows siRNA control experiments, in-
dicating that the alterations in endothelial permeability caused by JAM-C 
knockdown are specifi  c. Fig. S3 shows retina whole mounts from mice sub-
jected to the ROP model. Fig. S4 shows axial sections of the retina stained JEM VOL. 203, November 27, 2006  2713
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with periodic acid Schiff   and hematoxylin, indicating pathologic retinal neo-
vascularization. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20051730/DC1.
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